H.C. Wainwright analyst Mitchell S. Kapoor revised the price target on Alumis Inc (NASDAQ:ALMS) to $19.00, down from the previous target of $26.00, while retaining a Buy rating for the company's ...

H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza ...

H.C. Wainwright initiated coverage of Vertical Aerospace (EVTL) with a Buy rating and $12 price target The company specializes in designing ...

Equities researchers at StockNews.com initiated coverage on shares of SenesTech (NASDAQ:SNES – Get Free Report) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock ...

Fintel reports that on February 6, 2025, HC Wainwright & Co. initiated coverage of Harrow (NasdaqGM:HROW) with a Buy ...

On Tuesday, H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a price target of $180.00. According to InvestingPro data, this ...

HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will post earnings of $2.45 per share for the quarter, up from their previous forecast of $2.35.

On Wednesday, H.C. Wainwright reaffirmed a Buy rating on shares of TG Therapeutics (NASDAQ:TGTX) shares with a steady price target of $55.00. The firm's analyst highlighted the company's strong ...

On Monday, H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for ADC Therapeutics (NYSE:ADCT) stock, representing significant upside from the current price of $2.02. According to ...

On Monday, H.C. Wainwright adjusted its outlook on Eton Pharmaceuticals (NASDAQ:ETON), raising the price target to $17.00 from the previous $15.00 while maintaining a Buy rating on the company's ...